Table 2.

Characteristics of the 31 pediatric patients (≤18 yr old) who received benazepril 0.2 mg/kg per d (ACE-I group) or placeboa

CharacteristicACE-I Group(n = 12)Placebo Group(n = 19)
Age at randomization (yr; mean ± SD)15.8 ± 1.414.8 ± 2.7
Gender (male/female)10/212/7
CrCl (ml/min per 1.73 m2; mean ± SD)117.2 ± 29.0118.3 ± 13.0
eGFR (ml/min per 1.73 m2; mean ± SD)b114.4 ± 18.6111.4 ± 18.0
CrCl categories (ml/min per 1.73 m2; n [%])
    ≥90 (K/DOQI stage 1)11/12 (92)19/19 (100)
    60 to 89 (K/DOQI stage 2)1/12 (8)0
Proteinuria (g/d per 1.73 m2)1.6 ± 0.651.77 ± 0.79
Proteinuria categories (g/d per 1.73 m2; n [%])
    between 1.0 and 1.58/12 (67)11/19 (58)
    between 1.5 and 2.53/12 (25)4/19 (21)
    between 2.5 and 3.51/12 (8)4/19 (21)
ABPM: MAP (SDS)0.83 ± 0.90.11 ± 1.06
BP categories (n [%])c
    hypertension01/19 (5)
    high-normal BP00
    normotension12/12 (100)18/19 (95)
Follow-up (mo; median [range])46 (0 to 58)46.0 (3 to 53)
Follow-up (mo; median [range]), in 29 children with follow-up >3 mo47.0 (16 to 58)46.0 (3 to 53)
  • a No significant difference was found between the ACE-I and the placebo groups. SDS, SD score.

  • b Calculated from the Schwartz formula (21).

  • c Hypertension was classified according to the Task Force for Hypertension in Children, 1996 (23), considering hypertensive those with BP ≥95th centile for height and gender, high-normal those with BP between 90th and 94th centiles, and normal those with BP ≤90th centile.